CardioQ announcement

Deltex Medical Group PLC
01 October 2007


                            Deltex Medical Group plc


                CardioQ(TM)selected for NHS innovation initiative



1 October 2007 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the
UK's leading haemodynamic monitoring company, notes that the newly formed NHS
National Technology Adoption Hub has today announced that Deltex Medical's
CardioQ product is to be the subject of one of its first projects.


The NHS National Technology Adoption Hub has been established as a key element
of the NHS innovation agenda which is aimed at ensuring that NHS patients in
England benefit earlier from proven new medical technologies.


More information on the purpose and nature of the CardioQ project is expected to
be made available in the coming weeks.


Deltex Medical's Chief Executive, Andy Hill commented:


'This development puts CardioQ right at the top of the NHS's innovation agenda.
It is too early to predict the full impact of the NHS National Technology
Adoption Hub's work, however we are confident that it will prove to be a
material step towards CardioQ becoming a standard of care across the NHS.'


For further information, please contact:-

Deltex Medical Group plc               01243 774 837
Nigel Keen, Chairman                   [e-mail]
Andy Hill, Chief Executive             [e-mail]
Ewan Phillips, Finance Director        [e-mail]


Gavin Anderson & Company               0207 554 1400
Deborah Walter                         [e-mail]
Robert Speed                           [e-mail]


Charles Stanley Securities             020 7149 6000
Nominated Adviser
Philip Davies                          [e-mail]
Russell Cook                           [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM)monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.


The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works


   •Proved that the CardioQ works in a wide range of surgical procedures


   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


The SupraQ(TM)is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.






                      This information is provided by RNS
            The company news service from the London Stock Exchange